The signaling role of cd40 ligand in platelet biology and in platelet component transfusion

International Journal of Molecular Sciences

Volumn 15, Issue 12, 2014, Pages 22342-22364

  Aloui, Chaker ^a,b   Prigent, Antoine ^a,b   Sut, Caroline ^a   Tariket, Sofiane ^a   Hamzeh Cognasse, Hind ^a   Pozzetto, Bruno ^a   Richard, Yolande ^c,d   Cognasse, Fabrice ^a,b   Laradi, Sandrine ^a,b   Garraud, Olivier ^a,e  

^a UNIVERSITÉ DE LYON   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c INSTITUT COCHIN   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

Author keywords

CD40; CD40 ligand; Inflammation; Nuclear factor KappaB (NF B); p38 mitogen activated protein kinases (MAPK); Signaling pathways

Indexed keywords

BETA3 INTEGRIN; CD11B ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; MYELOPEROXIDASE; REACTIVE NITROGEN SPECIES;

B LYMPHOCYTE; ENZYME REGULATION; GENE STRUCTURE; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; NONHUMAN; PHYSIOLOGY; PROTEIN POLYMORPHISM; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; TRANSFUSION RELATED ACUTE LUNG INJURY; BIOLOGICAL MODEL; GENETICS; METABOLISM; THROMBOCYTE;

ANTIGENS, CD40; BLOOD PLATELETS; CD40 LIGAND; HUMANS; MODELS, BIOLOGICAL; PLATELET TRANSFUSION; SIGNAL TRANSDUCTION;

EID: 84919343500     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151222342     Document Type: Review

References (154)

1. Grewal, I.S.; Flavell, R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol.1998, 16, 111–135.
2. Banchereau, J.; Bazan, F.; Blanchard, D.; Brière, F.; Galizzi, J.P.; van Kooten, C.; Liu, Y.J.; Rousset, F.; Saeland, S. The CD40 antigen and its ligand. Annu. Rev. Immunol.1994, 12, 881–922.
3. Van Kooten, C.; Banchereau, J. CD40-CD40 ligand. J. Leukoc. Biol.2000, 67, 2–17.
4. Elgueta, R.; Benson, M.J.; de Vries, V.C.; Wasiuk, A.; Guo, Y.; Noelle, R.J. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev.2009, 229, 152–172.
5. Malarstig, A.; Lindahl, B.; Wallentin, L.; Siegbahn, A. Soluble CD40L levels are regulated by the −3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler. Thromb. Vasc. Biol.2006, 26, 1667–1673.
6. Phipps, R.P.; Kaufmann, J.; Blumberg, N. Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion. Lancet2001, 357, 2023–2024.
7. Blumberg, N.; Gettings, K.F.; Turner, C.; Heal, J.M.; Phipps, R.P. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion2006, 46, 1813–1821.
8. Blumberg, N.; Spinelli, S.L.; Francis, C.W.; Taubman, M.B.; Phipps, R.P. The platelet as an immune cell—CD40 ligand and transfusion immunomodulation. Immunol. Res.2009, 45, 251–260.
9. Cognasse, F.; Boussoulade, F.; Chavarin, P.; Acquart, S.; Fabrigli, P.; Lamy, B.; Garraud, O. Release of potential immunomodulatory factors during platelet storage. Transfusion2006, 46, 1184–1189.
10. Khan, S.Y.; Kelher, M.R.; Heal, J.M.; Blumberg, N.; Boshkov, L.K.; Phipps, R.; Gettings, K.F.; McLaughlin, N.J.; Silliman, C.C. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood2006, 108, 2455–2462.
11. Hamzeh-Cognasse, H.; Damien, P.; Nguyen, K.A.; Arthaud, C.-A.; Eyraud, M.-A.; Chavarin, P.; Absi, L.; Osselaer, J.-C.; Pozzetto, B.; Cognasse, F. et al. Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions. Transfusion2014, 54, 613–625.
12. Nguyen, K.A.; Hamzeh-Cognasse, H.; Sebban, M.; Fromont, E.; Chavarin, P.; Absi, L.; Pozzetto, B.; Cognasse, F.; Garraud, O. A computerized prediction model of hazardous inflammatory platelet transfusion outcomes. PLoS One2014, 9, e97082.
13. Antoniades, C.; Bakogiannis, C.; Tousoulis, D.; Antonopoulos, A.S.; Stefanadis, C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J. Am. Coll. Cardiol.2009, 54, 669–677.
14. Alaaeddine, N.; Hassan, G.S.; Yacoub, D.; Mourad, W. CD154: An immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis. Clin. Dev. Immunol. 2012, 2012, doi:10.1155/2012/490148.
15. Dejica, D.I.; Manea, E.M. Costimulatory molecule CD154 in systemic lupus erythematosus and rheumatoid arthritis. Therapeutic perspectives. Roum. Arch. Microbiol. Immunol.2006, 65, 66–74.
16. Zhang, B.; Wu, T.; Chen, M.; Zhou, Y.; Yi, D.; Guo, R. The CD40/CD40L system: A new therapeutic target for disease. Immunol. Lett.2013, 153, 58–61.
17. Locksley, R.M.; Killeen, N.; Lenardo, M.J. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell2001, 104, 487–501.
18. Anand, S.X.; Viles-Gonzalez, J.F.; Badimon, J.J.; Cavusoglu, E.; Marmur, J.D. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb. Haemost.2003, 90, 377–384.
19. Ludewig, B.; Henn, V.; Schröder, J.M.; Graf, D.; Kroczek, R.A. Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells. Eur. J. Immunol.1996, 26, 3137–3143.
20. Blair, P.J.; Riley, J.L.; Harlan, D.M.; Abe, R.; Tadaki, D.K.; Hoffmann, S.C.; White, L.; Francomano, T.; Perfetto, S.J.; Kirk, A.D. et al. CD40 ligand (CD154) triggers a short-term CD4+ T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J. Exp. Med.2000, 191, 651–660.
21. Graf, D.; Müller, S.; Korthäuer, U.; van Kooten, C.; Weise, C.; Kroczek, R.A. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur. J. Immunol.1995, 25, 1749–1754.
22. Ensembl Genome Browser 77: Homo Sapiens-Summary-Gene: CD40LG (ENSG00000102245). Available Online: http://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENS G00000102245;r=X:136648193-136660390 (accessed on 8 October 2014).
23. Lievens, D.; Eijgelaar, W.J.; Biessen, E.A.L.; Daemen, M.J.A.P.; Lutgens, E. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb. Haemost.2009, 102, 206–214.
24. Ma, D.Y.; Clark, E.A. The role of CD40 and CD154/CD40L in dendritic cells. Semin. Immunol.2009, 21, 265–272.
25. Henn, V.; Slupsky, J.R.; Gräfe, M.; Anagnostopoulos, I.; Förster, R.; Müller-Berghaus, G.; Kroczek, R.A. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature1998, 391, 591–594.
26. Inwald, D.P. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ. Res.2003, 92, 1041–1048.
27. Girvin, A.M.; dal Canto, M.C.; Miller, S.D. CD40/CD40L interaction is essential for the induction of EAE in the absence of CD28-mediated co-stimulation. J. Autoimmun.2002, 18, 83–94.
28. Baker, R.L.; Wagner, D.H.; Haskins, K. CD40 on NOD CD4 T cells contributes to their activation and pathogenicity. J. Autoimmun.2008, 31, 385–392.
29. Vaitaitis, G.M.; Wagner, D.H. High distribution of CD40 and TRAF2 in Th40 T cell rafts leads to preferential survival of this auto-aggressive population in autoimmunity. PLoS One2008, 3, e2076.
30. Munroe, M.E. Functional roles for T cell CD40 in infection and autoimmune disease: The role of CD40 in lymphocyte homeostasis. Semin. Immunol.2009, 21, 283–288.
31. Tone, M.; Tone, Y.; Fairchild, P.J.; Wykes, M.; Waldmann, H. Regulation of CD40 function by its isoforms generated through alternative splicing. Proc. Natl. Acad. Sci. USA2001, 98, 1751–1756.
32. Hou, H.; Obregon, D.; Lou, D.; Ehrhart, J.; Fernandez, F.; Silver, A.; Tan, J. Modulation of neuronal differentiation by CD40 isoforms. Biochem. Biophys. Res. Commun.2008, 369, 641–647.
33. Chatzigeorgiou, A.E.; Lembessis, P.E.; Mylona-Karagianni, C.F.; Tsouvalas, E.A.; Diamanti-Kandarakis, E.; Kamper, E.F. CD40 expression and its association with low-grade inflammation in a Greek population of type 1 diabetic juveniles: Evidence for differences in CD40 mRNA isoforms expressed by peripheral blood mononuclear cells. Exp. Clin. Endocrinol. Diabetes2010, 118, 38–46.
34. Contin, C.; Pitard, V.; Itai, T.; Nagata, S.; Moreau, J.-F.; Déchanet-Merville, J. Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J. Biol. Chem.2003, 278, 32801–32809.
35. Eshel, D.; Toporik, A.; Efrati, T.; Nakav, S.; Chen, A.; Douvdevani, A. Characterization of natural human antagonistic soluble CD40 isoforms produced through alternative splicing. Mol. Immunol.2008, 46, 250–257.
36. Esposito, P.; Rampino, T.; dal Canton, A. Soluble CD40 as a modulator of CD40 pathway. Immunol. Lett.2012, 147, 85–86.
37. Reyes-Moreno, C.; Girouard, J.; Lapointe, R.; Darveau, A.; Mourad, W. CD40/CD40 homodimers are required for CD40-induced phosphatidylinositol 3-kinase-dependent expression of B7.2 by human B lymphocytes. J. Biol. Chem.2004, 279, 7799–7806.
38. Pullen, S.S.; Labadia, M.E.; Ingraham, R.H.; McWhirter, S.M.; Everdeen, D.S.; Alber, T.; Crute, J.J.; Kehry, M.R. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry1999, 38, 10168–10177.
39. He, X.; Xu, L.; Liu, Y. Enhancement of binding activity of soluble human CD40 to CD40 ligand through incorporation of an isoleucine zipper motif. Acta Pharmacol. Sin.2006, 27, 333–338.
40. Fullard, J.F. The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis. Curr. Pharm. Des.2004, 10, 1567–1576.
41. Scarborough, R.M.; Rose, J.W.; Hsu, M.A.; Phillips, D.R.; Fried, V.A.; Campbell, A.M.; Nannizzi, L.; Charo, I.F. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J. Biol. Chem.1991, 266, 9359–9362.
42. Zirlik, A.; Maier, C.; Gerdes, N.; MacFarlane, L.; Soosairajah, J.; Bavendiek, U.; Ahrens, I.; Ernst, S.; Bassler, N.; Missiou, A. et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation2007, 115, 1571–1580.
43. Léveillé, C.; Bouillon, M.; Guo, W.; Bolduc, J.; Sharif-Askari, E.; el-Fakhry, Y.; Reyes-Moreno, C.; Lapointe, R.; Merhi, Y.; Wilkins, J.A. et al. CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling. J. Biol. Chem.2007, 282, 5143–5151.
44. El Fakhry, Y.; Alturaihi, H.; Yacoub, D.; Liu, L.; Guo, W.; Leveillé, C.; Jung, D.; Khzam, L.B.; Merhi, Y.; Wilkins, J.A. et al. Functional interaction of CD154 protein with α5β1 integrin is totally independent from its binding to αIIbβ3 integrin and CD40 molecules. J. Biol. Chem.2012, 287, 18055–18066.
45. Hassan, G.S.; Merhi, Y.; Mourad, W.M. CD154 and its receptors in inflammatory vascular pathologies. Trends Immunol. 2009, 30, 165–172.
46. Ledbetter, J.A.; Shu, G.; Gallagher, M.; Clark, E.A. Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40). J. Immunol.1987, 138, 788–794.
47. Durandy, A.; Kracker, S.; Fischer, A. Primary antibody deficiencies. Nat. Rev. Immunol.2013, 13, 519–533.
48. Nutt, S.L.; Tarlinton, D.M. Germinal center B and follicular helper T cells: siblings, cousins or just good friends? Nat. Immunol.2011, 12, 472–477.
49. Baumjohann, D.; Preite, S.; Reboldi, A.; Ronchi, F.; Ansel, K.M.; Lanzavecchia, A.; Sallusto, F. Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity2013, 38, 596–605.
50. Bhadra, R.; Gigley, J.P.; Khan, I.A. Cutting edge: CD40-CD40 ligand pathway plays a critical CD8-intrinsic and -extrinsic role during rescue of exhausted CD8 T cells. J. Immunol.2011, 187, 4421–4425.
51. Korniluk, A.; Kemona, H.; Dymicka-Piekarska, V. Multifunctional CD40L: Pro- and anti-neoplastic activity. Tumour Biol. 2014, 35, 9447–9457.
52. Nagy, B.; Miszti-Blasius, K.; Kerenyi, A.; Clemetson, K.J.; Kappelmayer, J. Potential therapeutic targeting of platelet-mediated cellular interactions in atherosclerosis and inflammation. Curr. Med. Chem.2012, 19, 518–531.
53. Prasad, K.S.S.; Andre, P.; Yan, Y.; Phillips, D.R. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr. Opin. Hematol.2003, 10, 356–361.
54. Pamukcu, B.; Lip, G.Y.H.; Snezhitskiy, V.; Shantsila, E. The CD40-CD40L system in cardiovascular disease. Ann. Med.2011, 43, 331–340.
55. Lievens, D.; Zernecke, A.; Seijkens, T.; Soehnlein, O.; Beckers, L.; Munnix, I.C.A.; Wijnands, E.; Goossens, P.; van Kruchten, R.; Thevissen, L. et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood2010, 116, 4317–4327.
56. Nurden, A.T. Platelets, inflammation and tissue regeneration. Thromb. Haemost. 2011, 105 (Suppl. 1), S13–S33.
57. Sanguigni, V.; Ferro, D.; Pignatelli, P.; del Ben, M.; Nadia, T.; Saliola, M.; Sorge, R.; Violi, F. CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia. J. Am. Coll. Cardiol.2005, 45, 35–42.
58. Levi, M.; van der Poll, T.; Büller, H.R. Bidirectional relation between inflammation and coagulation. Circulation2004, 109, 2698–2704.
59. Miller, D.L.; Yaron, R.; Yellin, M.J. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J. Leukoc. Biol.1998, 63, 373–379.
60. Chen, Y.; Chen, J.; Xiong, Y.; Da, Q.; Xu, Y.; Jiang, X.; Tang, H. Internalization of CD40 regulates its signal transduction in vascular endothelial cells. Biochem. Biophys. Res. Commun.2006, 345, 106–117.
61. Chen, C.; Chai, H.; Wang, X.; Jiang, J.; Jamaluddin, M.S.; Liao, D.; Zhang, Y.; Wang, H.; Bharadwaj, U.; Zhang, S. et al. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood2008, 112, 3205–3216.
62. Gururajan, P.; Gurumurthy, P.; Nayar, P.; Babu, S.; Sarasabharati, A.; Victor, D.; Cherian, K.M. Increased serum concentrations of Soluble CD40 Ligand as a prognostic marker in patients with Acute Coronary Syndrome. Indian J. Clin. Biochem.2009, 24, 229–233.
63. Xu, H.; Zhang, X.; Mannon, R.B.; Kirk, A.D. Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J. Clin. Investig.2006, 116, 769–774.
64. Toubi, E.; Shoenfeld, Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity2004, 37, 457–464.
65. André, P.; Nannizzi-Alaimo, L.; Prasad, S.K.; Phillips, D.R. Platelet-derived CD40L: The switch-hitting player of cardiovascular disease. Circulation2002, 106, 896–899.
66. André, P.; Prasad, K.S.S.; Denis, C.V.; He, M.; Papalia, J.M.; Hynes, R.O.; Phillips, D.R.; Wagner, D.D. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat. Med.2002, 8, 247–252.
67. Prasad, K.S.; Andre, P.; He, M.; Bao, M.; Manganello, J.; Phillips, D.R. Soluble CD40 ligand induces β3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc. Natl. Acad. Sci. USA2003, 100, 12367–12371.
68. May, A.E.; Kälsch, T.; Massberg, S.; Herouy, Y.; Schmidt, R.; Gawaz, M. Engagement of glycoprotein IIb/IIIa (α(IIb)β3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation2002, 106, 2111–2117.
69. Chakrabarti, S.; Varghese, S.; Vitseva, O.; Tanriverdi, K.; Freedman, J.E. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler. Thromb. Vasc. Biol.2005, 25, 2428–2434.
70. Li, G.; Sanders, J.M.; Bevard, M.H.; Sun, Z.; Chumley, J.W.; Galkina, E.V.; Ley, K.; Sarembock, I.J. CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am. J. Pathol.2008, 172, 1141–1152.
71. Tung, J.-P.; Fraser, J.F.; Nataatmadja, M.; Colebourne, K.I.; Barnett, A.G.; Glenister, K.M.; Zhou, A.Y.; Wood, P.; Silliman, C.C.; Fung, Y.L. Age of blood and recipient factors determine the severity of transfusion-related acute lung injury (TRALI). Crit. Care 2012, 16, doi:10.1186/cc11178.
72. Rahman, M.; Zhang, S.; Chew, M.; Ersson, A.; Jeppsson, B.; Thorlacius, H. Platelet-derived CD40L (CD154) mediates neutrophil upregulation of Mac-1 and recruitment in septic lung injury. Ann. Surg.2009, 250, 783–790.
73. Vlaar, A.P.J.; Juffermans, N.P. Transfusion-related acute lung injury: a clinical review. Lancet2013, 382, 984–994.
74. Hidalgo, A.; Chang, J.; Jang, J.-E.; Peired, A.J.; Chiang, E.Y.; Frenette, P.S. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat. Med.2009, 15, 384–391.
75. Hassan, G.S.; Merhi, Y.; Mourad, W. CD40 ligand: A neo-inflammatory molecule in vascular diseases. Immunobiology2012, 217, 521–532.
76. Hermann, A. Platelet CD40 ligand (CD40L)—subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets2001, 12, 74–82.
77. Danese, S.; Sans, M.; Fiocchi, C. The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut2004, 53, 1035–1043.
78. Charafeddine, A.H.; Kim, E.J.; Maynard, D.M.; Yi, H.; Weaver, T.A.; Gunay-Aygun, M.; Russell, M.; Gahl, W.A.; Kirk, A.D. Platelet-derived CD154: Ultrastructural localization and clinical correlation in organ transplantation. Am. J. Transplant.2012, 12, 3143–3151.
79. Doescher, A.; Petershofen, E.K.; Hertenstein, B.; Kraemer, D.; Casper, J.; Schmidt, J.-P.; Müller, T.H. Platelet recovery and survival measured in patients by quantitative polymerase chain reaction of mitochondrial DNA. Transfusion2014, doi:10.1111/trf.12778.
80. Denis, M.M.; Tolley, N.D.; Bunting, M.; Schwertz, H.; Jiang, H.; Lindemann, S.; Yost, C.C.; Rubner, F.J.; Albertine, K.H.; Swoboda, K.J. et al. Escaping the nuclear confines: Signal-dependent pre-mRNA splicing in anucleate platelets. Cell2005, 122, 379–391.
81. Nurden, A.T.; Nurden, P.; Sanchez, M.; Andia, I.; Anitua, E. Platelets and wound healing. Front. Biosci. J. Virtual Libr.2008, 13, 3532–3548.
82. Plé, H.; Maltais, M.; Corduan, A.; Rousseau, G.; Madore, F.; Provost, P. Alteration of the platelet transcriptome in chronic kidney disease. Thromb. Haemost.2012, 108, 605–615.
83. Garraud, O.; Berthet, J.; Hamzeh-Cognasse, H.; Cognasse, F. Pathogen sensing, subsequent signalling, and signalosome in human platelets. Thromb. Res.2011, 127, 283–286.
84. Gnatenko, D.V.; Dunn, J.J.; McCorkle, S.R.; Weissmann, D.; Perrotta, P.L.; Bahou, W.F. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood2003, 101, 2285–2293.
85. Rowley, J.W.; Oler, A.J.; Tolley, N.D.; Hunter, B.N.; Low, E.N.; Nix, D.A.; Yost, C.C.; Zimmerman, G.A.; Weyrich, A.S. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood2011, 118, e101–e111.
86. Simon, L.M.; Edelstein, L.C.; Nagalla, S.; Woodley, A.B.; Chen, E.S.; Kong, X.; Ma, L.; Fortina, P.; Kunapuli, S.; Holinstat, M. et al. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood2014, 123, e37–e45.
87. Nagalla, S.; Shaw, C.; Kong, X.; Kondkar, A.A.; Edelstein, L.C.; Ma, L.; Chen, J.; McKnight, G.S.; López, J.A.; Yang, L. et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood2011, 117, 5189–5197.
88. Flaumenhaft, R. Molecular basis of platelet granule secretion. Arterioscler. Thromb. Vasc. Biol.2003, 23, 1152–1160.
89. Rendu, F.; Brohard-Bohn, B. The platelet release reaction: granules’ constituents, secretion and functions. Platelets2001, 12, 261–273.
90. Blair, P.; Flaumenhaft, R. Platelet α-granules: Basic biology and clinical correlates. Blood Rev. 2009, 23, 177–189.
91. Jackson, S.P.; Nesbitt, W.S.; Westein, E. Dynamics of platelet thrombus formation. J. Thromb. Haemost.2009, 7, 17–20.
92. Henn, V.; Steinbach, S.; Büchner, K.; Presek, P.; Kroczek, R.A. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood2001, 98, 1047–1054.
93. Elzey, B.D.; Grant, J.F.; Sinn, H.W.; Nieswandt, B.; Waldschmidt, T.J.; Ratliff, T.L. Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation. J. Leukoc. Biol.2005, 78, 80–84.
94. Elzey, B.D.; Tian, J.; Jensen, R.J.; Swanson, A.K.; Lees, J.R.; Lentz, S.R.; Stein, C.S.; Nieswandt, B.; Wang, Y.; Davidson, B.L. et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity2003, 19, 9–19.
95. Cognasse, F.; Hamzeh-Cognasse, H.; Lafarge, S.; Chavarin, P.; Cogné, M.; Richard, Y.; Garraud, O. Human platelets can activate peripheral blood B cells and increase production of immunoglobulins. Exp. Hematol.2007, 35, 1376–1387.
96. Leroyer, A.S.; Rautou, P.-E.; Silvestre, J.-S.; Castier, Y.; Lesèche, G.; Devue, C.; Duriez, M.; Brandes, R.P.; Lutgens, E.; Tedgui, A. et al. CD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J. Am. Coll. Cardiol.2008, 52, 1302–1311.
97. Danese, S.; Katz, J.A.; Saibeni, S.; Papa, A.; Gasbarrini, A.; Vecchi, M.; Fiocchi, C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut2003, 52, 1435–1441.
98. Viallard, J.-F.; Solanilla, A.; Gauthier, B.; Contin, C.; Déchanet, J.; Grosset, C.; Moreau, J.-F.; Praloran, V.; Nurden, P.; Pellegrin, J.-L. et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood2002, 99, 2612–2614.
99. Chaturvedi, R.; Gupta, M.; Jain, A.; Das, T.; Prashar, S. Soluble CD40 ligand: A novel biomarker in the pathogenesis of periodontal disease. Clin. Oral Investig. 2014, doi:10.1007/s00784-014-1216-3.
100. Galicia López, A.; Olguín Ortega, L.; Saavedra, M.A.; Méndez Cruz, R.; Jimenez Flores, R.; García de la Peña, M. Increased concentrations of soluble CD40 ligand platelet in patients with primary antiphospholipidic syndrome. Reumatol. Clin. 2013, 9, 216–220.
101. Kim, H.O.; Kim, H.-S.; Youn, J.-C.; Shin, E.-C.; Park, S. Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays. J. Transl. Med. 2011, 9, doi:10.1186/1479-5876-9-113.
102. Li, Z.; Delaney, M.K.; O’Brien, K.A.; Du, X. Signaling during platelet adhesion and activation. Arterioscler. Thromb. Vasc. Biol.2010, 30, 2341–2349.
103. Varga-Szabo, D.; Pleines, I.; Nieswandt, B. Cell Adhesion mechanisms in platelets. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 403–412.
104. Rivera, J.; Lozano, M. L.; Navarro-Núñez, L.; Vicente, V. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica2009, 94, 700–711.
105. Thon, J.N.; Schubert, P.; Devine, D.V. Platelet storage lesion: A new understanding from a proteomic perspective. Transfus. Med. Rev.2008, 22, 268–279.
106. Dzieciatkowska, M.; D’Alessandro, A.; Burke, T.A.; Kelher, M.R.; Moore, E.E.; Banerjee, A.; Silliman, C.C.; West, B.F.; Hansen, K.C. Proteomics of apheresis platelet supernatants during routine storage: Gender-related differences. J. Proteomics2014, 112C, 190–209.
107. Ohto, H.; Nollet, K.E. Overview on platelet preservation: Better controls over storage lesion. Transfus. Apher. Sci.2011, 44, 321–325.
108. Estebanell, E.; Díaz-Ricart, M.; Escolar, G.; Lozano, M.; Mazzara, R.; Ordinas, A. Alterations in cytoskeletal organization and tyrosine phosphorylation in platelet concentrates prepared by the buffy coat method. Transfusion2000, 40, 535–542.
109. Schubert, P.; Thon, J.N.; Walsh, G.M.; Chen, C.H.I.; Moore, E.D.; Devine, D.V.; Kast, J. A signaling pathway contributing to platelet storage lesion development: targeting PI3-kinase-dependent Rap1 activation slows storage-induced platelet deterioration. Transfusion2009, 49, 1944–1955.
110. Canault, M.; Duerschmied, D.; Brill, A.; Stefanini, L.; Schatzberg, D.; Cifuni, S.M.; Bergmeier, W.; Wagner, D.D. p38 mitogen-activated protein kinase activation during platelet storage: Consequences for platelet recovery and hemostatic function in vivo. Blood2010, 115, 1835–1842.
111. Escolar, G.; White, J.G. Changes in glycoprotein expression after platelet activation: Differences between in vitro and in vivo studies. Thromb. Haemost.2000, 83, 371–386.
112. Kasirer-Friede, A.; Kahn, M.L.; Shattil, S.J. Platelet integrins and immunoreceptors. Immunol. Rev.2007, 218, 247–264.
113. Kageyama, Y.; Doi, T.; Matsushima-Nishiwaki, R.; Iida, Y.; Akamatsu, S.; Kondo, A.; Kuroyanagi, G.; Yamamoto, N.; Mizutani, J.; Otsuka, T. et al. Involvement of Rac in thromboxane A2-induced human platelet activation: Regulation of sCD40 ligand release and PDGF-AB secretion. Mol. Med. Rep. 2014, doi:10.3892/mmr.2014.2143.
114. Panzer, S. Differential response to LPS isotypes induced platelet activation mediated by Toll-like receptor (TLR)-4. Clin. Immunol.2013, 146, 13–14.
115. Rivadeneyra, L.; Carestia, A.; Etulain, J.; Pozner, R.G.; Fondevila, C; Negrotto, S.; Schattner, M. Regulation of platelet responses triggered by Toll-like receptor 2 and 4 ligands is another non-genomic role of nuclear factor-KB. Thromb. Res.2014, 133, 235-243.
116. Berthet, J.; Damien, P.; Hamzeh-Cognasse, H.; Arthaud, C.-A.; Eyraud, M.-A.; Zéni, F.; Pozzetto, B.; McNicol, A.; Garraud, O.; Cognasse, F. Human platelets can discriminate between various bacterial LPS isoforms via TLR4 signaling and differential cytokine secretion. Clin. Immunol.2012, 145, 189-200.
117. Otterdal, K.; Pedersen, T.M.; Solum, N.O. Release of soluble CD40 ligand after platelet activation: Studies on the solubilization phase. Thromb. Res.2004, 114, 167-177.
118. Jin, Y.; Nonoyama, S.; Morio, T.; Imai, K.; Ochs, H.D.; Mizutani, S. Characterization of soluble CD40 ligand released from human activated platelets. J. Med. Dent. Sci.2001, 48, 23-27.
119. Mason, P.J.; Chakrabarti, S.; Albers, A.A.; Rex, S.; Vitseva, O.; Varghese, S.; Freedman, J.E. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am. J. Cardiol.2005, 96, 1365-1369.
120. Santos-Martínez, M.J.; Medina, C.; Jurasz, P.; Radomski, M.W. Role of metalloproteinases in platelet function. Thromb. Res.2008, 121, 535-542.
121. Matthies, K.M.G.; Newman, J.L.; Hodzic, A.; Wingett, D.G. Differential regulation of soluble and membrane CD40L proteins in T cells. Cell. Immunol.2006, 241, 47-58.
122. Yacoub, D.; Benslimane, N.; Al-Zoobi, L.; Hassan, G; Nadiri, A.; Mourad, W. CD154 is released from T-cells by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and ADAM17 in a CD40 protein-dependent manner. J. Biol. Chem.2013, 288, 36083-36093.
123. Furman, M.I.; Krueger, L.A.; Linden, M.D.; Barnard, MR.; Frelinger, A.L.; Michelson, A.D. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J. Am. Coll. Cardiol.2004, 43, 2319-2325.
124. Reinboldt, S.; Wenzel, F.; Rauch, B.H.; Hohlfeld, T.; Grandoch, M.; Fischer, J.W.; Weber, A.-A. Preliminary evidence for a matrix metalloproteinase-2 (MMP-2)-dependent shedding of soluble CD40 ligand (sCD40L) from activated platelets. Platelets2009, 20, 441-444.
125. Wenzel, F.; Rox, J.; Reinboldt, S.; Weber, A.A.; Giers, G.; Fischer, J. Release of soluble CD40L by matrix metalloprotease-2 (MMP-2)-dependent shedding of platelets and its subsequent accumulation in stem cell products of autologous donors. J. Stem Cells Regen. Med.2010, 6, 66-67.
126. Choi, W.S.; Jeon, O.H.; Kim, D.S. CD40 ligand shedding is regulated by interaction between matrix metalloproteinase-2 and platelet integrin a(IIb)P(3). J. Thromb. Haemost.2010, 8, 1364-1371.
127. Rahman, M.; Roller, J.; Zhang, S.; Syk, I.; Menger, M.D.; Jeppsson, B.; Thorlacius, H. Metalloproteinases regulate CD40L shedding from platelets and pulmonary recruitment of neutrophils in abdominal sepsis. Inflamm. Res.2012, 61, 571-579.
128. Rahman, M.; Zhang, S.; Chew, M.; Syk, I.; Jeppsson, B.; Thorlacius, H. Platelet shedding of CD40L is regulated by matrix metalloproteinase-9 in abdominal sepsis. J. Thromb. Haemost.2013, 11, 1385-1398.
129. Menchén, L.; Marín-Jiménez, I.; Arias-Salgado, E.G.; Fontela, T.; Hernández-Sampelayo, P.; Rodríguez, M.C.G.; Butta, N.V. Matrix metalloproteinase 9 is involved in Crohn’s disease-associated platelet hyperactivation through the release of soluble CD40 ligand. Gut2009, 58, 920–928.
130. Fernández Bello, I.; Álvarez, M.T.; López-Longo, F.J.; Arias-Salgado, E.G.; Martín, M.; Jiménez-Yuste, V.; Rodríguez de la Rúa, A.; Butta, N.V. Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease patients. Thromb. Haemost.2012, 107, 88–98.
131. Nannizzi-Alaimo, L.; Alves, V.L.; Phillips, D.R. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation2003, 107, 1123–1128.
132. Yacoub, D.; Hachem, A.; Théorêt, J.-F.; Gillis, M.-A.; Mourad, W.; Merhi, Y. Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway. Arterioscler. Thromb. Vasc. Biol.2010, 30, 2424–2433.
133. Hachem, A.; Yacoub, D.; Zaid, Y.; Mourad, W.; Merhi, Y. Involvement of nuclear factor κB in platelet CD40 signaling. Biochem. Biophys. Res. Commun.2012, 425, 58–63.
134. Karim, Z.A.; Zhang, J.; Banerjee, M.; Chicka, M.C.; Al Hawas, R.; Hamilton, T.R.; Roche, P.A.; Whiteheart, S.W. IκB kinase phosphorylation of SNAP-23 controls platelet secretion. Blood2013, 121, 4567–4574.
135. Ren, Q.; Ye, S.; Whiteheart, S.W. The platelet release reaction: Just when you thought platelet secretion was simple. Curr. Opin. Hematol.2008, 15, 537–541.
136. Broos, K.; Feys, H.B.; de Meyer, S.F.; Vanhoorelbeke, K.; Deckmyn, H. Platelets at work in primary hemostasis. Blood Rev. 2011, 25, 155–167.
137. Vamvakas, E.C.; Blajchman, M.A. Prestorage versus poststorage white cell reduction for the prevention of the deleterious immunomodulatory effects of allogeneic blood transfusion. Transfus. Med. Rev.2000, 14, 23–33.
138. Zhang, M.; Lu, S.; Wu, X.; Chen, Y.; Song, X.; Jin, Z.; Li, H.; Zhou, Y.; Chen, F.; Huo, Y. Multimarker approach for the prediction of cardiovascular events in patients with mild to moderate coronary artery lesions. A 3-year follow-up study. Int. Heart. J.2012, 53, 85–90.
139. Zhao, W.; Zhang, F.; Li, Z.; Yu, H.; Li, Z.; Gao, W. Soluble CD40 ligand is associated with angiographic severity of coronary artery disease in patients with acute coronary syndrome. Chin. Med. J.2014, 127, 2218–2221.
140. Gerdes, S.; Osadtschy, S.; Buhles, N.; Baurecht, H.; Mrowietz, U. Cardiovascular biomarkers in patients with psoriasis. Exp. Dermatol.2014, 23, 322–325.
141. Zahn, D.; Petrak, F.; Uhl, I.; Juckel, G.; Neubauer, H.; Hägele, A.-K.; Wiltfang, J.; Herpertz, S. New pathways of increased cardiovascular risk in depression: a pilot study on the association of high-sensitivity C-reactive protein with pro-atherosclerotic markers in patients with depression. J. Affect. Disord.2013, 146, 420–425.
142. Ferroni, P.; Riondino, S.; Vazzana, N.; Santoro, N.; Guadagni, F.; Davì, G. Biomarkers of platelet activation in acute coronary syndromes. Thromb. Haemost.2012, 108, 1109–1123.
143. Panichi, V.; Scatena, A.; Migliori, M.; Marchetti, V.; Paoletti, S.; Beati, S. Biomarkers of chronic inflammatory state in uremia and cardiovascular disease. Int. J. Inflamm. 2012, 2012, doi:10.1155/2012/360147.
144. Devine, D.V.; Serrano, K. The platelet storage lesion. Clin. Lab. Med.2010, 30, 475–487.
145. Shrivastava, M. The platelet storage lesion. Transfus. Apher. Sci.2009, 41, 105–113.
146. Cognasse, F.; Hamzeh-Cognasse, H.; Lafarge, S.; Acquart, S.; Chavarin, P.; Courbil, R.; Fabrigli, P.; Garraud, O. Donor platelets stored for at least 3 days can elicit activation marker expression by the recipient’s blood mononuclear cells: An in vitro study. Transfusion2009, 49, 91–98.
147. Hamzeh-Cognasse, H.; Cognasse, F.; Palle, S.; Chavarin, P.; Olivier, T.; Delézay, O.; Pozzetto, B.; Garraud, O. Direct contact of platelets and their released products exert different effects on human dendritic cell maturation. BMC Immunol. 2008, 9, doi:10.1186/1471-2172-9-54.
148. National Agency of Security of the Drug and Health Products. Available online: http://ansm.sante.fr/Mediatheque/Publications/Informations-recentes (accessed on 2 December 2014).
149. Tuinman, P.R.; Gerards, M.C.; Jongsma, G.; Vlaar, A.P.; Boon, L.; Juffermans, N.P. Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury. Clin. Exp. Immunol.2011, 165, 278–284.
150. Wang, C.; Mody, M.; Herst, R.; Sher, G.; Freedman, J. Flow cytometric analysis of platelet function in stored platelet concentrates. Transfus. Sci.1999, 20, 129–139.
151. Aloui, C.; Sut, C.; Prigent, A.; Fagan, J.; Cognasse, F.; Granados-Herbepin, V.; Touraine, R.; Pozzetto, B.; Aouni, M.; Fendri, C. et al. Genotyping of polymorphisms responsible for the regulation of the expression of CD40 ligand in two blood donor populations (Auvergne-Loire, France; Sousse and Monastir, Tunisia). Transfus. Clin. Biol.2013, 20, 293–294.
152. Tanaka, S.; Hayashi, T.; Tani, Y.; Hirayama, F. Removal by adsorbent beads of biological response modifiers released from platelets, accumulated during storage, and potentially associated with platelet transfusion reactions. Transfusion2010, 50, 1096–1105.
153. Tanaka, S.; Hayashi, T.; Tani, Y.; Hirayama, F. Removal of biological response modifiers associated with platelet transfusion reactions by columns containing adsorption beads. Transfusion2014, 54, 1790–1797.
154. Couzin, J. Magnificent obsession. Science2005, 307, 1712–1715.